Detalles de la búsqueda
1.
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Lipids Health Dis
; 15(1): 116, 2016 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27405296
2.
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Clin Ther
; 31(1): 115-22, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19243712
3.
Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
Cardiology
; 114(3): 192-8, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19602880
4.
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Am J Cardiol
; 99(12): 1706-1713, 2007 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17560879
5.
Striated muscle safety of ezetimibe/simvastatin (Vytorin).
Am J Cardiol
; 97(2): 223-8, 2006 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16442367
6.
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Clin Ther
; 28(6): 849-59, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16860168
7.
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Curr Med Res Opin
; 22(5): 823-35, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16709304
8.
Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.
J Clin Lipidol
; 9(3): 313-25, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26073389
9.
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
Vasc Health Risk Manag
; 11: 165-72, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25750540
10.
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Am Heart J
; 148(3): 447-55, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15389231
11.
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
Am J Cardiol
; 90(9): 942-6, 2002 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12398959
12.
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Clin Ther
; 25(6): 1670-86, 2003 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12860491
13.
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Clin Ther
; 26(3): 379-89, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15110130
14.
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Curr Med Res Opin
; 20(9): 1437-45, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15383192
15.
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Clin Cardiol
; 26(11): 509-14, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14640465
16.
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Clin Cardiol
; 26(1): 18-24, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12539808
17.
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Int J Cardiol
; 167(1): 225-31, 2013 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22305632
18.
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Am J Cardiovasc Drugs
; 12(3): 197-206, 2012 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22500948
19.
Effectiveness and safety of laropiprant on niacin-induced flushing.
Am J Cardiol
; 110(6): 817-22, 2012 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22683042
20.
Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
J Clin Lipidol
; 5(4): 281-7, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21784373